Gentian Diagnostics ASA (GENT.OL)

NOK 39.0

(0.0%)

Market Cap (In NOK)

601.47 Million

Revenue (In NOK)

136.19 Million

Net Income (In NOK)

-10.64 Million

Avg. Volume

8662.00

Currency
NOK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
34.8-61.0
PE
-
EPS
-
Beta Value
0.556
ISIN
NO0010748866
CUSIP
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Njaal Kind
Employee Count
-
Website
https://www.gentian.com
Ipo Date
2016-12-14
Details
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.